首页> 美国卫生研究院文献>Advances in Hematology >Pathogenetic Clinical and Prognostic Features of Adult t(4;11)(q21;q23)/MLL-AF4 Positive B-Cell Acute Lymphoblastic Leukemia
【2h】

Pathogenetic Clinical and Prognostic Features of Adult t(4;11)(q21;q23)/MLL-AF4 Positive B-Cell Acute Lymphoblastic Leukemia

机译:成人t(4; 11)(q21; q23)/ MLL-AF4阳性B细胞急性淋巴细胞白血病的发病机制临床及预后特征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Translocation t(4;11)(q21;q23) leading to formation of MLL-AF4 fusion gene is found in about 10% of newly diagnosed B-cell acute lymphoblastic leukemia (ALL) in adult patients. Patients expressing this chromosomal aberration present typical biological, immunophenotypic, and clinical features. This form of leukemia is universally recognized as high-risk leukemia and treatment intensification with allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission (CR) could be a valid option to improve prognosis, but data obtained from the literature are controversial. In this review, we briefly describe pathogenetic, clinical, and prognostic characteristics of adult t(4;11)(q21;q23)/MLL-AF4 positive ALL and provide a review of the clinical outcome reported by the most important cooperative groups worldwide.
机译:成年患者中约10%的新诊断B细胞急性淋巴细胞白血病(ALL)中发现易位t(4; 11)(q21; q23),导致形成MLL-AF4融合基因。表达这种染色体畸变的患者表现出典型的生物学,免疫表型和临床特征。这种形式的白血病已被普遍认为是高危白血病,在首次完全缓解(CR)时采用异基因造血干细胞移植(HSCT)进行的治疗强化可能是改善预后的有效选择,但从文献中获得的数据仍存在争议。在这篇综述中,我们简要描述了成年t(4; 11)(q21; q23)/ MLL-AF4阳性ALL的致病性,临床和预后特征,并对全球最重要的合作组织报告的临床结果进行了综述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号